title: Vortioxetine (Brintellix®) and levomilnacipran (Fetzima®): the two newest additions to the antidepressant formulary.
abstract: In the final months of 2013, the US Food and Drug Administration approved two new antidepressant formulations. This column presents a review of the pertinent literature on both: vortioxetine (Brintellix(®)) and levomilnacipran (Fetzima(®)).
authors.affiliation: The University of Tennessee, College of Nursing , Knoxville, Tennessee , USA.
authors.forename: Marian W
authors.initials: MW
authors.lastname: Roman
authors.forename: Shannon M
authors.initials: SM
authors.lastname: Wilkinson
mesh_terms: D000928:Antidepressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D003521:Cyclopropanes / Q000009:adverse effects / Q000627:therapeutic use*; D003865:Major Depressive Disorder / Q000175:diagnosis / Q000188:drug therapy* / Q000451:nursing* / Q000523:psychology; D017277:Drug Approval; D006801:Humans; D000078764:Milnacipran; D010879:Piperazines / Q000009:adverse effects / Q000627:therapeutic use*; D013440:Sulfides / Q000009:adverse effects / Q000627:therapeutic use*; D014481:United States; D014486:United States Food and Drug Administration; D000078784:Vortioxetine
chemical_list: D000928:Antidepressive Agents; D003521:Cyclopropanes; D010879:Piperazines; D013440:Sulfides; D000078784:Vortioxetine; D000078764:Milnacipran